292
Views
20
CrossRef citations to date
0
Altmetric
Review

Bupropion: risks and benefits

&
Pages 995-1003 | Published online: 28 Oct 2005

  • JORENBY D: Clinical efficacy of bupropion in the management of smokingcessation. Drugs (2002) 62\(Suppl. 2):25–35.
  • •A comprehensive review of the efficacy of bupropion.
  • DOLL R, PETO R, BOREHAM J, SUTHERLAND I: Mortality in relation to smoking: 50 years' observations on male British doctors. BE Med. (2004) 328:1519.
  • EDWARDS R: The problem of tobacco smoking. Br. Med. J. (2004) 328:217–219.
  • NATIONAL INSTITUTE OF CLINICAL EXCELLENCE: Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. NICE report (2002) No. 39.
  • •UK guidelines on treatments for smoking cessation.
  • NO AUTHORS LISTED: A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA (2000) 283:3244–3254.
  • FAGERSTROM K: The epidemiology of smoking: health consequences and benefits of cessation. Drugs (2002) 62\(Suppl. 2):l–9.
  • HAYS JT, EBBERT JO: Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs (2003) 17:71–83.
  • LIGHTWOOD JM, PHIBBS CS, GLANTZ SA: Short-term health and economic benefits of smoking cessation: low birth weight. Pediatrics (1999) 104:1312–1320.
  • LIGHT WOOD JM, GLANTZ SA: Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation (1997) 96:1089–1096.
  • WARING WS: The role of pharmacotherapy in assisting smoking cessation. Eur. Clin. Pharmacy]. (2003) 59:351–356.
  • SILAGY C, STEAD LF: Physician advice for smoking cessation. Cochrane Database Syst. Rev (2004) (4):CD000165.
  • LANCASTER T, STEAD LF: Individual behavioural counselling for smoking cessation. Cochrane Database Syst. Rev (2005) (2):CD001292.
  • RICE VH, STEAD LF: Nursing interventions for smoking cessation. Cochrane Database Syst. Rev (2004) (1):CD001188.
  • SUTHERLAND G: Current approaches to the management of smoking cessation. Drugs (2002) 62\(Suppl. 2):53–61.
  • WHITE AR, RAMPES H, ERNST E: Acupuncture for smoking cessation. Cochrane Database Syst. Rev (2002) (2):CD000009.
  • SILAGY C, LANCASTER T, STEAD L, MANT D, FOWLER G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev (2004) (3):CD000146.
  • HUGHES JR, STEAD LF, LANCASTER T: Antidepressants for smoking cessation. Cochrane Database Syst. Rev (2004) (4):CD000031.
  • •Cochrane review of smoking cessation therapies.
  • GOURLAY SG, STEAD LF, BENOWITZ NL. Clonidine for smoking cessation. Cochrane Database Syst. Rev (2004) (3):CD000058.
  • HOLM KJ, SPENCER CM: Bupropion: a review of its use in the management of smoking cessation. Drugs (2000) 59:1007–1024.
  • BALFOUR DJ: The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. J. Clin.Pjct. (2001) 55:53–57.
  • JOHNSTON AJ, ASCHER J, LEADBETTER R et al: Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs (2002) 62\(Suppl. 2):11–24.
  • TASHKIN D, KANNER R, BAILEY W et al.: Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet (2001) 357:1571–1575.
  • HURT RD, SACHS DP, GLOVER ED et al.: A comparison of sustained-release bupropion and placebo for smoking cessation. NEIM (1997) 337:1195–1202.
  • TONSTAD S, FARSANG C, KLAENE G et al:Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur. Heart J. (2003) 24:946–955.
  • HALL SM, HUMFLEET GL, REUS VI, MUNOZ RE HARTZ DT, MAUDE-GRIFFIN R: Psychological intervention and antidepressant treatment in smoking cessation. Arch. Gen. Psychiatry (2002) 59:930–936.
  • JORENBY DE, LEISCHOW SJ, NIDES MA et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. NEIM (1999) 340:685–691.
  • HAYS JT, HURT RD, RIGOTTI NA, NIAURA R et al: Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomised, controlled trial. Ann. Intern. Med. (2001) 135:423–433.
  • CHENGAPPA KN, KAMBHAMPATI RK, PERKINS K et al. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychiatry (2001) 62:503–508.
  • HAYFORD KE, PATTEN CA, RUMMANS TA et al.: Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br. Psychiatry (1999) 174:173–178.
  • HERTZBERG MA, MOORE SD, FELDMAN ME, BECKHAM JC: A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. Clin. Psychopharmacol (2001) 21:94–98.
  • EVINS AE, MAYS VK, RIGOTTI NA, TISDALE T, CATHER C, GOFF DC: A pilot trial of bupropion added to cognitive behavioural therapy for smoking cessation in schizophrenia. Nicotine Tob. Res. (2001) 3:397–403.
  • WEINER E, BALL MP, SUMMERFELT A, GOLD J, BUCHANAN RW: Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am. I Psychiatry (2001) 158:635–637.
  • HAYS JT: Tobacco dependence treatment in patients with heart and lung disease: implications for intervention and review of pharmacological therapy. I Cardiopulmon rehabil (2000) 20:215–223.
  • ASCHER JA, COLE JO, COLIN JN, FEIGHNER JP, FERRIS RM, FIBIGER HC et al.: Bupropion: a review of its mechanism of antidepressant activity. Clin Psychiatry (1995) 56:395–401.
  • BOSHIER A, WILTON LV, SHAKIR SA: Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur. j Clin Pharmacol (2003) 59:767–773.
  • •Drug Safety Research Unit UK investigation of bupropion safety.
  • AUBIN HJ: Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs (2002) 62\(Suppl. 2):45–52.
  • COMMITTEE ON SAFETY OF MEDICINES: Zyban (bupropion) - safety reminder. Curr. Prob. Pharmacovig. (2001) 27:5.
  • GODFREY C, FOWLER G: Pharmacoeconomic considerations in the management of smoking cessation. Drugs (2002) 62\(Suppl. 2):63–70.
  • •A review of pharmacoeconomics of smoking cessation in the UK setting.
  • PARROTT S, GODFREY C: Economics of smoking cessation. Br. Med. J. (2004) 328:947–949.
  • BARENDREGT JJ, BONNEUX L, VAN DER MAAS PJ: The health care costs of smoking. NEIM (1997) 337:1052–1057.
  • http://emc.medicines.org.uldemciassetsici htmliclisplaydoc.asp?documentid=2948 Zyban (SPC) (2005).
  • http://medicines.mhra.gov.uldourworld monitorsafequalmedisafetymessagesi zyban26702.pdf CSM: Zyban safety update (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.